Recent Company News

• 08:55 AM ET Apr 02, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:37 AM ET May 30, 2025
  

  BioLineRx upgraded to buy from hold at Jones ($3.79, 0.00)

• 07:04 AM ET May 30, 2025
  

  BioLineRx announces new pilot phase data from Phase 2 combination trial of motixafortide in first line PDAC to be presented at ASCO (2.20a, 0.00)

• 07:06 AM ET May 27, 2025
  

  BioLineRx reports Q1 EPS $0.00 vs FactSet $0.00 [2 est, ($0.00)-(0.00)] (2.20a, 0.00)

• 07:00 AM ET May 27, 2025
  

  BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

• 07:00 AM ET May 20, 2025
  

  BioLineRx to Report First Quarter 2025 Results on May 27, 2025

• 04:57 PM ET Apr 01, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:20 PM ET Apr 01, 2025
  

  BioLineRx downgraded to hold from buy at Jones ($2.92, 0.00)